21.   Subsequent Events

The Company has evaluated all events subsequent to the balance sheet date through the date of filing this Quarterly Report. During this period, there were no material subsequent events requiring disclosure except as discussed below.

​

Warrant Exercises

​

In October 2025, Lynx1 Master Fund elected a cashless exercise of 1,260,570 of the Pre-Funded Warrant shares. Pursuant to the terms of the Pre-Funded Warrant, 1,260,488 shares of Common Stock were issued. Upon delivery of the shares, no further shares remain issuable under the Pre-Funded Warrant.

​

Stock Options

​

On October 20, 2025, the Board approved stock option agreements for its officers to purchase an aggregate of 310,000 shares of Common Stock at an exercise price of $0.893 per share, which included a grant of 180,000 stock options to Martin Brenner, the Company’s Chief Executive Officer and Chief Scientific Officer, a grant of 75,000 stock options to Felipe Duran, the Company’s Chief Financial Officer, and a grant of 55,000 stock options to Marc Banjak, the Company’s Chief Legal Officer. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.

Series G Warrant Exercises

In October 2025, 4,250,000 Series G Warrants were exercised whereby the holders elected to receive 4,250,000 pre-funded warrants in lieu of shares of Common Stock, together with Series H Warrants to purchase up to 4,250,000 shares of Common Stock for gross proceeds of approximately $3.0 million. The pre-funded warrants issued upon this election have an exercise price of $0.001 and are immediately exercisable. See Note 15 – Stockholders’ Equity for additional information.

2025 Pre-Funded Warrants

In October 2025, 972,221 of the 2025 Pre-Funded Warrants were exercised for proceeds of approximately $972.

​

​